TOTAL VOLUME:
$95.2b
24H VOL:
$189,315,480
24H TRANSACTIONS:
906,796,923
OPEN INTEREST:
$1,999,983,951
797,912
Markets across
13,530
events
MATCHED EVENTS:
789
PLATFORM COVERAGE:
5
Polymarket:
45%
VS.
Kalshi:
55%
FDA approves Outlook Therapeutics' ONS-5010? Odds & Prediction Markets
98%
chance
Time left: 16d:02h:47m
FDA approves Outlook Therapeutics' ONS-5010?
$
$20
$50
$100
$500
Description
As of market creation, the FDA's expected decision date for the specified application is July 29, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Outlook Therapeutics's ONS-5010 as a treatment for wet age-related macular degeneration by August 12, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is July 29, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Outlook Therapeutics's ONS-5010 as a treatment for wet age-related macular degeneration by August 12, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds and traditional analyst forecasts often diverge because they operate on different timelines and incentive structures. Analysts publish periodic reports based on clinical evidence and regulatory precedent, while prediction market traders continuously reprice based on breaking news and sentiment shifts. This market aggregates real-money bets from participants with skin in the game, which can lead to faster reaction times than consensus analyst views. However, both sources attempt to estimate the same underlying probability: FDA approval of ONS-5010. Comparing current market odds to recent analyst assessments can reveal whether traders are pricing in more optimism or caution than the research community.
This market resolves around Jul 29, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. The resolution hinges on an official FDA decision regarding ONS-5010 approval status. Traders holding approval shares win if the agency grants marketing authorization; rejection shares win if the application is denied or withdrawn. The timeframe allows for the full FDA review cycle, including potential advisory committee meetings and post-submission interactions. Once a definitive regulatory decision is announced through official FDA channels or company disclosure, the market settles accordingly.
Clinical trial updates, FDA meeting minutes, and regulatory communications are primary catalysts for price movement in this market. Positive Phase 3 data or favorable feedback from the FDA during pre-approval meetings would likely boost approval odds, while safety concerns or requests for additional studies could reduce them. Competitive approvals in the same therapeutic area may also influence trader sentiment. Company earnings calls, analyst upgrades or downgrades, and broader biotech sector trends can shift risk appetite. Patent developments, manufacturing milestones, and leadership changes at Outlook Therapeutics represent secondary signals. Traders monitor all available information to adjust positions ahead of major regulatory milestones or announcements.
Follow the signals, not the noise
Get insights on market conviction, notable shifts, and what the data is quietly signaling.